NCT03598244View on ClinicalTrials.gov

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2026

Conditions
Recurrent Diffuse Intrinsic Pontine GliomaRecurrent Malignant GliomaRecurrent MedulloblastomaRecurrent Primary Central Nervous System NeoplasmRefractory Diffuse Intrinsic Pontine GliomaRefractory Malignant GliomaRefractory MedulloblastomaRefractory Primary Central Nervous System Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scan

DRUG

Savolitinib

Given PO

PROCEDURE

X-Ray Imaging

Undergo X-ray imaging

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

38105

Saint Jude Children's Research Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH